### National Cancer Institute Slovakia



### Translational Research Unit Slovakia



# Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.

<u>Mego M</u><sup>1, 2</sup>, Karaba M<sup>2</sup>, Cierna Z<sup>1</sup>, Janega P<sup>1</sup>, Minarik G<sup>1</sup>, Benca J<sup>2</sup>, Sedl‡ckov‡ T<sup>1</sup>, Manasova D<sup>1</sup>, Gronesova P<sup>3</sup>, Pechan J<sup>2,4</sup>, Reuben JM<sup>5</sup>, Mardiak J<sup>1, 2</sup>

<sup>1</sup> Faculty of Medicine, Comenius University, Bratislava, Slovakia, <sup>2</sup>National Cancer Institute, Bratislava, Slovakia, <sup>3</sup>Cancer Research Institute, Bratislava, Slovakia, <sup>4</sup> Slovak Medical University, <sup>5</sup> University of Texas MD Anderson Cancer Center, Houston, Texas, USA

### Matrix metalloproteinase 1 (MMP1)

- zinc-dependent endopeptidase
- collagen-cleaving MMP
- cleave extracellular matrix components
- produced by tumor cells and tumor associated stroma
- high MMP1 expression in tumor is associated with:
  - Đ tumor evolution
  - Đ poor prognosis
  - **Đ** shortened survival
  - Đ induction of epithelial to mesenchymal transition

## **MMPs and EMT**



Radisky et al. J Mammary Gland Biol Neoplasia. 2010, 15: 201-12



### Mannello F. BMC Med. 2011 Aug 11;9:95.

### **CTC** heterogeneity



Different methods detect different CTC subpopulations with different clinical and biological value

All data regarding CTCs, should be interpreted within the context of the detection method used.

Mego M, Mani SA, Cristofanilli M. Nat Rev Clin Oncol, 2010

## Factors affecting CTC count



Mego M, Mani SA, Cristofanilli M. Nat Rev Clin Oncol, 2010

## Study hypothesis

We hypothesize that MMP1 is involved in CTC release, and CTC are detected more often in breast cancer patients with high MMP1 expression in primary tumor.

## Study aims

- To assess association between CTC and MMP1 expression in breast cancer cells
- To assess association between CTC and MMP1 expression in tumor stroma
- To correlate MMP1 expression and patients` tumor characteristics

**CTC** detection



Mego, et al. Int J Cancer, 2012

### MMP1 expression scoring

- Immunohistochemical staining was quantified using a weighted histoscore.
- The proportion of cells with nuclear staining was multiplied by the intensity of staining to provide a score of 0–300.
- Score = (0 x % not stained) + (1 x % weakly stained)
  + (2 x % moderately stained) + (3 x % strongly stained)

## MMP1 expression scoring



staining intensity 0



staining intensity 2



staining intensity 1



staining intensity 3

## Patients` characteristics

	%	
All patients (N = 100)	100.0	
Invasive ductal carcinoma	e ductal carcinoma 86	
T1	66	
> T1	33	
N0	57	
N1-3	43	
ER/PR positive	87	
HER2 positive	16	
Triple negative	15	
Grade 3	36	

## **CTC** detection

Gene expression	% samples
KRT 19	12
SNAIL1	0
SLUG	13
TWIST	2
ZEB1	0
Circulating tumor cells	% patients
All CTC	24
Epithelial CTC	12
EMT CTC	14
Both CTC	2

### CTC and MMP1 expression in cancer cells

MMP1 and Epithelial CTC p = 0.58 $100^{-100$ 









# MMP1 expression in cancer cells and tumor characteristics

MMP1 expression and tumor grade



MMP1 and Ki67





MMP1 and triple negative (TN) breast cancer



## Multivariate analysis

Independent variable	Regression coefficient	Standard error	p-value
<b>EMT_CTC</b> (present vs. absent)	30.1	17.1	0.08
<b>Ki 67</b> (cut-off 14%) (low vs. high)	39.8	11.8	0.001

### CTC and MMP1 expression in stromal cells

MMP1 expression and epithelial CTC p = 0.3  $f_{00}$   $f_{00}$ 

#### MMP1 expression and EMT\_CTC



MMP1 expression and any CTC



# MMP1 expression in stromal cells and tumor characteristics



## Conclusions

- High MMP1 expression in breast cancer cells, but not in cancer stroma was associated with CTC\_EMT in peripheral blood
- High MMP1 expression is associated with more aggressive biological features including increased proliferation, hormone receptor negativity and high grade.
- Our data suggest a link between MMP1 and CTCs with EMT phenotype, and further support a role for MMPs and EMT in tumor dissemination.

### **Acknowledgements**

### National Cancer Institute, Slovakia

#### **Department of Oncology**

Michal Mego Jozef Mardiak Jozef Sufliarsky Zlatica Péková Zuzana Hlavata Eva Oravcova Andrej Jurik Tomas Minarik Iveta Oravcova Michaela Kubičková Veronika Švábová

#### **Department of Surgery**

Marian Karaba Juraj Benca Juraj Pechan

#### **Translational Research Unit**

Denisa Maňasová Daniela Svetlovska

#### **Department of Pathology**

Gabriela Sieberová Ján Macúch Michal Majerčík Peter Jáni

## Comenius University, Faculty of Medicine

Department of Pathology Zuzana Čierna Pavol Janega Ludovit Danihel Pavel Babal

Institute of molecular biomedicine Gabriel Minárik Tatiana Sedlačková

### Cancer Research Institute, Slovak Academy of Sciences Paulína Gronesová

Ivana Fridrichová

### MD Anderson Cancer Center

James M Reuben

### Jefferson Medical College, Philadelphia Massimo Cristofanilli

## Thank you for your attention

Jednotka Translačného Výskumu



http://www.fmed.uniba.sk/index.php?id=2201